Literature DB >> 11096218

Electrophysiological, neuropsychological and clinical findings in multiple sclerosis patients receiving interferon beta-1b: a 1-year follow-up.

W Gerschlager1, R Beisteiner, L Deecke, G Dirnberger, W Endl, H Kollegger, G Lindinger, K Vass, W Lang.   

Abstract

We assessed serial event-related potentials (ERPs) as well as neuropsychological and clinical test findings in a group of multiple sclerosis (MS) patients (n = 14) treated with interferon beta-1b (INF-beta-1b) compared to normal controls (n = 14). All investigations were done within 1 week before INF-beta-1b therapy was started and 12 months later. An auditory oddball paradigm was employed. No significant differences in the N100, P200, N200 or P300 latencies between patients and control group were found, but 3 out of 14 MS patients developed abnormal P300 latencies (more than 2 standard errors from the mean) after 1 year of INF-beta-1b therapy. This was not reflected by the respective neurological impairment as assessed by the Expanded Disability Status Scale score. ERPs might be a useful tool in clinical studies in order to evaluate drug effects on cognition, but for a final statement, the analysis of ERPs in a larger group of patients is required. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096218     DOI: 10.1159/000008237

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  6 in total

Review 1.  Neurophysiological correlates of cognitive disturbances in multiple sclerosis.

Authors:  Letizia Leocani; Javier J Gonzalez-Rosa; Giancarlo Comi
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

Review 2.  [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].

Authors:  H-P Hartung; J Haas; M Meergans; F Tracik; S Ortler
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214

Review 3.  Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.

Authors:  Hayrettin Tumani; Ingo Uttner
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

4.  Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis.

Authors:  Hanni Kiiski; Richard B Reilly; Róisín Lonergan; Siobhán Kelly; Marie Claire O'Brien; Katie Kinsella; Jessica Bramham; Teresa Burke; Seán O Donnchadha; Hugh Nolan; Michael Hutchinson; Niall Tubridy; Robert Whelan
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

5.  Differential cognitive impairment for diverse forms of multiple sclerosis.

Authors:  Javier J Gonzalez-Rosa; Manuel Vazquez-Marrufo; Encarnacion Vaquero; Pablo Duque; Monica Borges; Miguel A Gamero; Carlos M Gomez; Guillermo Izquierdo
Journal:  BMC Neurosci       Date:  2006-05-19       Impact factor: 3.288

6.  Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.

Authors:  Michelle H Chen; Yael Goverover; Helen M Genova; John DeLuca
Journal:  CNS Drugs       Date:  2020-06       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.